Please assess the completion status of the following clinical trial:

Trial Title: Bosutinib For Autosomal Dominant Polycystic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 to 50 years old at the time of consent.~* Documented diagnosis of ADPKD (PKD-1 or PKD-2 genotypes allowed).~* Total kidney volume ≥ 750 cc, as measured by centrally evaluated MRI.~Exclusion Criteria:~* eGFR \< 60 mL/min/1.73m2.~* Uncontrolled hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg).~* Any previous exposure to the bosutinib test article or receipt of other polycystic kidney disease (PKD) therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): None
- Cohort B (Type: EXPERIMENTAL): None
- Cohort C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).